source
- ICER reports two-thirds of new drugs launched 2022-2025 priced well above cost-effectiveness thresholdsICER’s latest analysis of launch prices for new prescription medicines shows a sharp rise in net costs between 2022 and 2025. After adjusting for inflation, the median price climbed from $190,000 i…
- Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic porphyriaDisc Medicine announced that its experimental therapy bitopertin achieved its primary and secondary goals in a Phase 3 trial for erythropoietic porphyria, a rare condition that makes patients extre…